Selective phosphodiesterase inhibitors modulate the activity of alveolar macrophages from sensitized guinea-pigs

European Respiratory Journal

Volumn 12, Issue 6, 1998, Pages 1334-1339

  Germain, N ^a   Berlin, B ^b   Legendre, A ^a   Martin, B ^b   Lagente, V ^a   Payne, A ^b   Boichot, E ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

^b Institut de Recherche Jouveinal   (France)

Author keywords

Alveolar macrophage; Guinea pig; Selective phosphodiesterase inhibitor

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; 8 BROMO CYCLIC GMP; ARACHIDONIC ACID; BUCLADESINE; CYCLIC AMP; FORMYLMETHIONYLLEUCYLPHENYLALANINE; MILRINONE; OVALBUMIN; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; ROLIPRAM;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GUINEA PIG; LUNG ALVEOLUS MACROPHAGE; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

4-(3-BUTOXY-4-METHOXYBENZYL)-2-IMIDAZOLIDINONE; 8-BROMO CYCLIC ADENOSINE MONOPHOSPHATE; ALLERGENS; ANIMALS; ARACHIDONIC ACID; BRONCHOALVEOLAR LAVAGE FLUID; BUCLADESINE; CYCLIC AMP; GUINEA PIGS; ISOENZYMES; MACROPHAGES, ALVEOLAR; MALE; MILRINONE; OVALBUMIN; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PYRROLIDINONES; RESPIRATORY HYPERSENSITIVITY; ROLIPRAM;

EID: 0032422331     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.98.12061334     Document Type: Article

References (31)

1. Beavo JA, Conti M, Heaslip RJ. Multiple cyclic nucleotide phosphodiesterase. Mol Pharmacol 1994; 46: 399-405.
2. Bolger GB. Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes. Cell Signalling 1994; 6: 851-859.
3. Banner KH, Page CP. Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma. Eur Respir J 1995; 8: 996-1000.
4. Nicholson CD, Shahid M. Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Their potential utility in the therapy of asthma. Pulm Pharmacol 1994; 6: 1-17.
5. Teixeira MM, Gristwood RW, Cooper N, Hellewell PG. Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol Sci 1997; 18: 164-171.
6. Hichami A, Boichot E, Germain N, Legrand A, Moodley I, Lagente V. Involvement of cyclic AMP in the effects of phosphodiesterase IV inhibitors on arachidonate release. Eur J Pharmacol 1995; 291: 91-97.
7. Banner KH, Roberts NM, Page CP. Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis. Br J Pharmacol 1995; 116: 3169-3174.
8. Gantner F, Kupferschmidt R, Schudt C, Wendel A, Hatzelmann A. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumor necrosis factor-α release by PDE inhibitors. Br J Pharmacol 1997; 121: 221-231.
9. Hatzelmann A, Engelsädtter R, Morley J, Mazzoni I. Enzymatic and functional aspects of dual selective PDE 3/4 inhibitors. In: Schudt C, Dent G, Rabe KF, eds. Phosphodiesterase Inhibitors. London, Academic Press, 1996; pp. 147-160.
10. Lee TH, Lane SJ. The role of macrophages in the mechanism of airway inflammation in asthma. Am Rev Respir Dis 1992; 145: S27-S30.
11. Lohmann-Mathes ML, Steinmüller C, Franke-Ullman G. Pulmonary macrophages. Eur Respir J 1994; 7: 1678-1689.
12. Boichot E, Lagente V, Paubert-Braquet M, Frossard N. Inhaled substance P induces activation of alveolar macrophages and increases airway responses in the guinea-pig. Neuropeptides 1993; 25: 307-313.
13. Lagente V, Boichot E, Chadli S, Dugas B, Mencia-Huerta JM, Braquet P. Effect of the platelet-activating factor antagonist, BN 50730, on the increased production of superoxide anions by alveolar macrophages from antigen-exposed sensitized guinea-pigs. Fund Clin Pharmacol 1991; 5: 426.
14. Boichot E, Lagente V, Carre C, Waltmann P, Mencia-Huerta JM, Braquet P. Bronchial hyperresponsiveness and cellular infiltration in the lung of guinea-pigs sensitized and challenged by aerosol. Clin Exp Allergy 1991; 21: 67-76.
15. Lavan BE, Lakey T, Houslay MD. Resolution and soluble cyclic nuclcotide phosphodiesterase isoenzymes, from liver and hepatocytes, identifies a novel IBMX-insensitive form. Biochem Pharmacol 1989; 38: 4123-4136.
16. Lagente V, Moodley I, Perrin S, Mottin G, Junien JL. Effects of isozyme-selective phosphodiesterase inhibitors on eosinophil infiltration in the guinea-pig lung. Eur J Pharmacol 1994; 255: 253-256.
17. Holgate ST, Djukanovic R, Wilson J, Roche W, Roche PH, Howarth PH. Inflammatory processes and bronchial hyperresponsiveness. Clin Exp Allergy 1991; 21: Suppl. 1, 30-36.
18. Cluzel M, Damon M, Chanez P, et al. Enhanced alveolar cell luminol dependent chemiluminescence in asthma. J Allergy Clin Immunol 1987; 80: 195-201.
19. Tonnel AB, Cosset P, Joseph M, Fournier E, Capron A. Stimulation of alveolar macrophages in asthmatic patients after local provocation tests. Lancet 1983; i: 1406-1408.
20. Dent G, Giembycz MA, Wolf B, Rabe KF, Barnes PJ, Magnussen H. Identification of PDE III and PDE IV isoenzymes of cAMP PDE in human alveolar macrophages. Am Rev Respir Dis 1993; 147: A184.
21. Tenor H, Hatzelmann A, Kupferschmidt R, et al. Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages. Clin Exp Allergy 1995; 25: 625-633.
22. Elliott KFR, Leonhard EJ. Interactions of formylmethionyl-leucyl-phenylalanine, adenosine and phosphodiesterase inhibitors in human monocytes. Effects on superoxide release, inositol phosphates and cAMP. FEBS Lett 1989; 254: 94-98.
23. Torphy TJ, Zhou H, Cieslinski LB. Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity. J Pharmacol Exp Ther 1992; 263: 1195-1205.
24. Chan SC, Reifsnyder D, Beavo JA, Hanifin JM. Immunochemical characterization of the distinct monocyte cyclic AMP phosphodiesterase from patients with atopic dermatitis. J Allergy Clin Immunol 1993; 91: 1179-1188.
25. Barnes PJ. Cyclic nucleotides and phosphodiesterases and airway function. Eur Respir J 1995; 8: 457-462.
26. Butler J, Chan SC, Stevens S, Hanifin M. Increased histamine release associated with elevated cAMP phosphodiesterase activity in atopic dermatitis. J Allergy Clin Immunol 1983; 71: 490-497.
27. Grewe SR, Chan SC, Hanifin JM. Elevated leukocyte cyclic AMP phosphodiesterase in atopic disease: a possible mechanism for cAMP-agonist hyperresponsiveness. J Allergy Clin Immunol 1982; 70: 452-457.
28. Holden CA, Chan SC, Hanifin JM. Monocyte localization of elevated cAMP phosphodiesterase activity in atopic dermatitis. J Invest Dermatol 1986; 87: 372-376.
29. Beusenberg FD, Adolfs MJP, Van Schaik A, Van Amsterdam JGC, Bonta IL. Antigen challenge modifies the cyclic AMP response of inflammatory mediators and β-adrenergic drugs in alveolar macrophages. Eur J Pharmacol 1989; 174: 33-41.
30. Banner KH, Moriggi E, Da Ros B, Schioppacassi G, Semeraro C, Page CP. The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established antiasthma drugs on inflammatory cell activation. Br J Pharmacol 1996; 119: 1255-1261.
31. Lagente V, Pruniaux MP, Junien JL, Moodley I. Modulation of cytokine-induced eosinophil infiltration by phosphodiesterase inhibitors. Am J Respir Crit Care Med 1995; 151: 1720-1724.